Business
Mesoblast treatment gets US panel’s key tick of approval – Sydney Morning Herald
The drug that Mesoblast has been trialling on some COVID-19 patients has just got the nod from a US regulator panel for treating children with severe responses to bone marrow transplants.
Stem cell treatment producer Mesoblast has recorded a significant win after the US FDA’s Oncologic Drugs Advisory Committee voted in favour of its flagship product for treating children with severe responses to bone marrow transplants.
The planned meeting of the US regulator had sent Mesoblast shares on a rollercoaster this week. The multi-billion company’s share price dropped more than 30 per cent in a single session on Tuesday after briefing papers released ahead of the meeting revealed the w…
-
Noosa News15 hours agoTwo in five Brisbane streets have no footpaths, with council building about 4km of new paths last year
-
Business24 hours agoWhere to invest $20,000 in ASX ETFs for 2026 and beyond
-
General23 hours agoReece Walsh grabs the Sun to lead Brisbane to an all-time victory over Canberra
-
General22 hours agoBritish boxer and former world champion Ricky Hatton dies at age 46